Accuray touts study data in head-to-head between TomoTherapy and Varian ’ s RapidArc

Accuray (NSDQ:ARAY) today released data from a prospective study comparing its TomoTherapy intensity-modulated radiation therapy system with Varian Medical‘s (NYSE:VAR), RapidArc radiotherapy system, touting a higher survival rate for patients treated with its TomoTherapy system. Results from the study were published last month in the International Journal of Radiation Oncology – Biology – Physics. Accuray said that the 166-patient, multi-center study was the 1st to prospectively compare clinical outcomes across radiation platforms. In the study, 74 individuals were treated with the TomoTherapy system while 92 were treated with the RapidArc system. Loco-regional control, specific and overall survival were assessed up to 18 months post-treatment, as well as long-term toxicity and salivary function. Results indicated that patients treated with the TomoTherapy system were better, as measured by local control, cancer-specific survival and salivary function at 18 months. The company said that further analysis indicated a greater benefit in local control of larger tumors, and those which have spread to a high number of lymph nodes. “This is the 1st study to assess whether the method of delivering IMRT impacts the results we are able to achieve. In previous studies, we showed that TomoHelical was able to deliver radiation dose distributions which precisely conformed to the shape of the tumor with steep radiation fall-off outside the target. In this new stu...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Oncology Accuray Inc. Varian Medical Systems Source Type: news